These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
191 related articles for article (PubMed ID: 11190861)
1. [Estimation of the prevalence of Parkinson's disease in Asturia, Spain. A pharmacoepidemiological study of the consumption of antiparkinson drugs]. Martínez-Suárez MM; Blázquez-Menes B Rev Neurol; 2000 Dec 1-15; 31(11):1001-6. PubMed ID: 11190861 [TBL] [Abstract][Full Text] [Related]
2. [Use of antiparkinsonian agents in Castilla-La Mancha. Estimate of prevalence of Parkinson disease]. Criado-Alvarez JJ; Romo-Barrientos C; Martínez-Hernández J; González-Solana I Rev Neurol; 1998 Sep; 27(157):405-8. PubMed ID: 9774809 [TBL] [Abstract][Full Text] [Related]
3. [The estimation of prevalence of Parkinson disease in Navarra. An epidemiological study of the consumption of anti-parkinsonian drugs]. Artázcoz Sanz MT; Viñes Rueda JJ Rev Esp Salud Publica; 1995; 69(6):479-85. PubMed ID: 8789360 [TBL] [Abstract][Full Text] [Related]
4. [The prevalence and pharmacological cost of Parkinson's disease in Spain]. Abasolo-Osinaga E; Abecia-Inchaurregui LC; Fernández-Díaz E; Barcenilla-Laguna A; Bañares-Onraita T Rev Neurol; 2006 Dec 1-15; 43(11):641-5. PubMed ID: 17133323 [TBL] [Abstract][Full Text] [Related]
5. A pharmacoepidemiological study of the consumption of antiparkinson drugs in the Basque Autonomous Community (Spain) (1992-2004). Osinaga EA; Inchaurregui LC; Ikobaltzeta IE; Alonso NB; Del Pozo JG Parkinsonism Relat Disord; 2007 Dec; 13(8):500-4. PubMed ID: 17532251 [TBL] [Abstract][Full Text] [Related]
6. [The evolution of use of anti-Parkinson drugs in Spain]. Montané E; Vallano Ferraz A; Castel JM Rev Neurol; 2002 Apr 1-15; 34(7):612-7. PubMed ID: 12080509 [TBL] [Abstract][Full Text] [Related]
7. Population prevalence and incidence of Parkinson's disease in an Australian community. Mehta P; Kifley A; Wang JJ; Rochtchina E; Mitchell P; Sue CM Intern Med J; 2007 Dec; 37(12):812-4. PubMed ID: 17561942 [TBL] [Abstract][Full Text] [Related]
8. Use of antiparkinsonian drugs in Denmark: results from a nationwide pharmacoepidemiological study. Brandt-Christensen M; Kvist K; Nilsson FM; Andersen PK; Kessing LV Mov Disord; 2006 Aug; 21(8):1221-5. PubMed ID: 16671076 [TBL] [Abstract][Full Text] [Related]
9. Estimation of incidence and prevalence of Parkinson's disease in the elderly using pharmacy records. van de Vijver DA; Roos RA; Jansen PA; Porsius AJ; de Boer A Pharmacoepidemiol Drug Saf; 2001; 10(6):549-54. PubMed ID: 11828838 [TBL] [Abstract][Full Text] [Related]
11. [Daily defined doses of parkinsonian drugs in Alcoi]. Manzanares R; Matías-Guiu J; Provencio R; Falip R; López-Arlandis J; Martín R; Ruiz C Rev Neurol; 1996 Apr; 24(128):440-2. PubMed ID: 8721923 [TBL] [Abstract][Full Text] [Related]
12. [Estimate of type I bipolar disorder prevalence (1996-1998)]. Criado-Alvarez JJ; Domper Tornil JA; de la Rosa Rodríguez G Rev Esp Salud Publica; 2000; 74(2):131-8. PubMed ID: 10918804 [TBL] [Abstract][Full Text] [Related]
13. Punding prevalence in Parkinson's disease. Miyasaki JM; Al Hassan K; Lang AE; Voon V Mov Disord; 2007 Jun; 22(8):1179-81. PubMed ID: 17230464 [TBL] [Abstract][Full Text] [Related]
14. [Drug consumption in diabetes mellitus (I). Estimate of the therapeutic profile and the prevalence in the regions of Tarragona (548,900 inhabitants). Grup per a l'Estudi de la Diabetis a Tarragona]. Costa B; Utgés P; Monclús JF; Gomis T; Ciurana MR; Julve P Med Clin (Barc); 1992 Sep; 99(8):294-9. PubMed ID: 1453822 [TBL] [Abstract][Full Text] [Related]
15. Parkinson disease with old-age onset: a comparative study with subjects with middle-age onset. Diederich NJ; Moore CG; Leurgans SE; Chmura TA; Goetz CG Arch Neurol; 2003 Apr; 60(4):529-33. PubMed ID: 12707066 [TBL] [Abstract][Full Text] [Related]
16. Ongoing challenges to finding people with Parkinson's disease for epidemiological studies: a comparison of population-level case ascertainment methods. Harris MA; Koehoorn M; Teschke K Parkinsonism Relat Disord; 2011 Jul; 17(6):464-9. PubMed ID: 21531606 [TBL] [Abstract][Full Text] [Related]
17. Evaluation of healthcare utilization and health status of patients with Parkinson's disease treated with deep brain stimulation of the subthalamic nucleus. Spottke EA; Volkmann J; Lorenz D; Krack P; Smala AM; Sturm V; Gerstner A; Berger K; Hellwig D; Deuschl G; Freund HJ; Oertel WH; Dodel RC J Neurol; 2002 Jun; 249(6):759-66. PubMed ID: 12111311 [TBL] [Abstract][Full Text] [Related]
18. Comparison of chronic analgesic drugs prevalence in Parkinson's disease, other chronic diseases and the general population. Brefel-Courbon C; Grolleau S; Thalamas C; Bourrel R; Allaria-Lapierre V; Loï R; Micallef-Roll J; Lapeyre-Mestre M Pain; 2009 Jan; 141(1-2):14-8. PubMed ID: 19062167 [TBL] [Abstract][Full Text] [Related]
19. Adherence to antiparkinson medication in a multicenter European study. Grosset D; Antonini A; Canesi M; Pezzoli G; Lees A; Shaw K; Cubo E; Martinez-Martin P; Rascol O; Negre-Pages L; Senard A; Schwarz J; Strecker K; Reichmann H; Storch A; Löhle M; Stocchi F; Grosset K Mov Disord; 2009 Apr; 24(6):826-32. PubMed ID: 19191340 [TBL] [Abstract][Full Text] [Related]
20. The prevalence of Parkinson's disease in an area of North Tyneside in the North-East of England. Porter B; Macfarlane R; Unwin N; Walker R Neuroepidemiology; 2006; 26(3):156-61. PubMed ID: 16493203 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]